The dopamine (DA) transporter (DAT) is a plasma membrane glycoprotein expressed in dopaminergic (DA-) cells that takes back DA into presynaptic neurons after its release. DAT dysfunction has been involved in different neuro-psychiatric disorders including Parkinson's disease (PD). On the other hand, numerous studies support that the glial cell line-derived neurotrophic factor (GDNF) has a protective effect on DA-cells. However, studies in rodents show that prolonged GDNF over-expression may cause a tyrosine hydroxylase (TH, the limiting enzyme in DA synthesis) decline. The evidence of TH down-regulation suggests that another player in DA handling, DAT, may also be regulated by prolonged GDNF over-expression, and the possibility that this effect is induced at GDNF expression levels lower than those inducing TH down-regulation. This issue was investigated here using intrastriatal injections of a tetracycline-inducible adeno-associated viral vector expressing human GDNF cDNA (AAV-tetON-GDNF) in rats, and doxycycline (DOX; 0.01, 0.03, 0.5 and 3 mg/ml) in the drinking water during 5 weeks. We found that 3 mg/ml DOX promotes an increase in striatal GDNF expression of 12× basal GDNF levels and both DA uptake decrease and TH down-regulation in its native and Ser40 phosphorylated forms. However, 0.5 mg/ml DOX promotes a GDNF expression increase of 3× basal GDNF levels with DA uptake decrease but not TH down-regulation. The use of western-blot under non-reducing conditions, co-immunoprecipitation and in situ proximity ligation assay revealed that the DA uptake decrease is associated with the formation of DAT dimers and an increase in DAT-α-synuclein interactions, without changes in total DAT levels or its compartmental distribution. In conclusion, at appropriate GDNF transduction levels, DA uptake is regulated through DAT protein-protein interactions without interfering with DA synthesis.
Introduction
The uptake of dopamine (DA) into presynaptic terminals is the primary mechanism controlling the duration and intensity of DA signaling in post-and presynaptic DA receptors (Giros et al., 1996) . The DA transporter (DAT) is a plasma membrane glycoprotein expressed in dopaminergic (DA-) cells, responsible for DA uptake through a Na + /Cl − coupled cotransport mechanism (Giros and Caron, 1993; Freed et al., 1995) . DAT dysfunction has been involved in a number of neuropsychiatric disorders, including Parkinson's disease (PD) (Le Couteur et al., 1997; Bezard et al., 1999; Zahniser and Sorkin, 2009; Storch et al., 2004) . Taking into account that oxidative stress plays a central role in the pathogenesis of PD, that DA metabolism is the main source of reactive oxygen species in DA-cells, and that the cytosolic content in DA depends mostly on the DA uptake (Bannon, 2005) , DAT activity has been involved in DA-cell degeneration in PD. This idea is supported on the fact that midbrain DA-cells showing high susceptibility to degeneration contain higher levels of DAT mRNA and glycosylated (functional) DAT protein than those showing resistance (Uhl et al., 1994; Afonso-Oramas et al., 2009) . Moreover, DAT transports natural and synthetic DA analog neurotoxins, and its blockade or deficient expression makes DA-cells resistant to these neurotoxins (Bezard et al., 1999; Schober, 2004; Gonzalez-Hernandez et al., 2004; Afonso-Oramas et al., 2010) . 
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